MODEL PREDICTIONS FOR LIFETIME HEALTH BENEFITS OF MOBOCERTINIB AND CURRENT TREATMENT OPTIONS IN POST-PLATINUM PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC HARBORING EGFR EXON 20 INSERTION MUTATION IN CHINA

被引：0
|
作者：
Zuo, G. Y. [1 ]
Wang, Y. [2 ]
Gao, Y. [3 ]
Zhang, Y. J. [3 ]
Zhu, F. F. [3 ]
机构：
[1] Shandong Univ, Jinan, Peoples R China
[2] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[3] Takeda China Int Trading Co, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO214
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 17 条
  • [11] Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical Trial
    Zhou, Caicun
    Ramalingam, Suresh S.
    Kim, Tae Min
    Kim, Sang-We
    Yang, James Chih-Hsin
    Riely, Gregory J.
    Mekhail, Tarek
    Nguyen, Danny
    Campelo, Maria R. Garcia
    Felip, Enriqueta
    Vincent, Sylvie
    Jin, Shu
    Griffin, Celina
    Bunn, Veronica
    Lin, Jianchang
    Lin, Huamao M.
    Mehta, Minal
    Janne, Pasi A.
    JAMA ONCOLOGY, 2021, 7 (12) : 1772 - 1781
  • [12] Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non-small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.
    Janne, Pasi A.
    Ramalingam, Suresh S.
    Yang, James Chih-Hsin
    Riely, Gregory J.
    Bunn, Veronica
    Jin, Shu
    Zhou, Caicun
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [13] Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 study
    Popat, Sanjay
    Ramalingam, Suresh
    Kim, Tae Min
    Yang, James
    Riely, Gregory
    Mekhail, Tarek
    Nguyen, Danny
    Garcia Campelo, Maria Rosario
    Felip, Enriqueta
    Spira, Alexander
    Piotrowska, Zofia
    Bazhenova, Lyudmila
    Vincent, Sylvie
    Jin, Shu
    Griffin, Celina
    Diderichsen, Paul
    Gupta, Neeraj
    Bunn, Veronica
    Lin, Jianchang
    Lin, Huamao
    Churchill, Eric
    Mehta, Minal
    Zhou, Caicun
    Janne, Pasi
    LUNG CANCER, 2022, 165 : S30 - S31
  • [14] Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial (vol 7, e214761, 2021)
    Zhou, C.
    Ramalingam, S. S.
    Kim, T. M.
    JAMA ONCOLOGY, 2022,
  • [15] Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial (vol 7, e214761, 2021)
    Feng, Jean
    Friesner, Isabel
    Hong, Julian C.
    JAMA ONCOLOGY, 2024, 10 (10) : 1443 - 1443
  • [16] A COST-UTILITY ANALYSIS OF DACOMITINIB AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR EXON 21 L858R SUBSTITUTION MUTATION IN CHINA
    Jin, G.
    Zhao, J.
    Luan, L.
    Dong, P.
    Yang, L.
    VALUE IN HEALTH, 2021, 24 : S215 - S215
  • [17] Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).
    Li, Bob T.
    Ahn, Myung-Ju
    Goto, Koichi
    Mazieres, Julien
    Padda, Sukhmani Kaur
    William, Nassib William
    Wu, Yi-Long
    Dearden, Simon
    Ragone, Alejandra
    Viglianti, Natasha
    Gasco, Amaya
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12